Psilocybin-assisted psychotherapy (PAP) may be an effective intervention for a range of mental disorders. However, there appears to be a relative lack of qualitative evidence to complement emerging quantitative findings. To our knowledge, no reviews have systematically mapped the literature on qualitative studies on PAP for the treatment of mental disorders with the intent to identify opportunities for future research.
Aims:
To assess the scope of qualitative research on PAP for mental disorders, identify research trends, and highlight future opportunities.
Methods:
We conducted a systematic search of PubMed, Scopus, and PsycNET for qualitative studies of adults (18 years and older) with a mental disorder who received PAP in controlled research settings. The search was limited to peer review articles, without time limitations.
Results:
A total of 13 qualitative studies were identified, which included participants with depressive disorders, anxiety disorders, trauma- and stressor-related disorders, alcohol-use disorder, obsessive-compulsive disorder, and anorexia nervosa. The studies explored 12 topics, ranging from pre- to postintervention experiences. Most studies used semi-structured interviews and used interpretative phenomenological analysis or thematic analysis.
Conclusions:
This review provides information to researchers and clinicians to guide future qualitative investigations that will complement and enhance the field’s understanding of PAP in treating mental disorders. Opportunities include covering a broader range of mental disorders; exploring longer term outcomes, the sustainability of effects, postintervention support, and adverse experiences; comparing active and control group experiences; exploring therapist and significant other perspectives; and increasing sample sizes.
Castro SantosH, Gama MarquesJ. What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomed J, 2021; 6(1):e128; doi: 10.1097/j.pbj.0000000000000128
2.
IrizarryR, WinczuraA, DimassiO, et al.Psilocybin as a treatment for psychiatric Illness: A meta-analysis. Cureus, 2022; 14(11):e31796; doi: 10.7759/cureus.31796
3.
IsHakWW, GarciaP, PearlR, et al.The impact of psilocybin on patients experiencing psychiatric symptoms: A systematic review of randomized clinical trials. Innov Clin Neurosci, 2023; 20(4–6):39–48.
4.
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197; doi: 10.1177/0269881116675513
5.
HalberstadtAL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res, 2015; 277:99–120; doi: 10.1016/j.bbr.2014.07.016
6.
GriffithsRR, RichardsWA, McCannU, et al.Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl), 2006; 187(3):268–283; doi: 10.1007/s00213-006-0457-5
7.
CroweM, ManuelJ, CarlyleD, et al.Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. Int J Ment Health Nurs, 2023; 32(4):1025–1037; doi: 10.1111/inm.13127
8.
HortonDM, MorrisonB, SchmidtJ. Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. Am J Psychother, 2021; 74(4):140–149; doi: 10.1176/appi.psychotherapy.20220055
9.
Carhart-HarrisRL, FristonKJ. REBUS and the Anarchic brain: Toward a unified model of the brain action of psychedelicss. Pharmacol Rev, 2019; 71(3):316–344; doi: 10.1124/pr.118.017160
10.
LyC, GrebAC, CameronLP, et al.Psychedelics promote structural and functional neural plasticity. Cell Rep, 2018; 23(11):3170–3182; doi: 10.1016/j.celrep.2018.05.022
11.
FangS, YangX, ZhangW. Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Front Psychiatry, 2024; 15:1359088; doi: 10.3389/fpsyt.2024.1359088
12.
HaikazianS, Chen-LiDCJ, JohnsonDE, et al.Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Res, 2023; 329:115531; doi: 10.1016/j.psychres.2023.115531
13.
MetaxaA-M, ClarkeM. Efficacy of psilocybin for treating symptoms of depression: Systematic review and meta-analysis. BMJ, 2024; 385:e078084; doi: 10.1136/bmj-2023-078084
14.
WatfordT, MasoodN. Psilocybin, an effective treatment for major depressive disorder in adults—a systematic review. Clin Psychopharmacol Neurosci, 2024; 22(1):2–12; doi: 10.9758/cpn.23.1120
15.
KaminskiD, ReinertJP. The tolerability and safety of psilocybin in psychiatric and substance-dependence conditions: A systematic review. Ann Pharmacother, 2024; 58(8):811–826; doi: 10.1177/10600280231205645
16.
van der MeerPB, FuentesJJ, KapteinAA, et al.Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry, 2023; 14:1134454; doi: 10.3389/fpsyt.2023.1134454
17.
YuC-L, YangF-C, YangS-N, et al.Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis. Psychiatry Investig, 2021; 18(10):958–967; doi: 10.30773/pi.2021.0209
18.
MeikleSE, LiknaitzkyP, RossellSL, et al.Psilocybin-assisted therapy for depression: How do we advance the field? Aust N Z J Psychiatry, 2020; 54(3):225–231; doi: 10.1177/0004867419888575
19.
O’CallaghanC, HubikDJ, DwyerJ, et al.Experience of music used with psychedelic therapy: A rapid review and implications. J Music Ther, 2020; 57(3):282–314; doi: 10.1093/jmt/thaa006
20.
FinkelsteinC, SohaO, RoyA, et al.Why Would You Open Someone’s Brain up? Lived Experience Insights Inform a Psilocybin-Assisted Psychotherapy Treatment Manual for Body Image Disturbance, 2023; doi: 10.21203/rs.3.rs-3189970/v1
21.
BreeksemaJJ, NiemeijerA, KredietE, et al.Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: A qualitative study. Sci Rep, 2024; 14(1):2929; doi: 10.1038/s41598-024-53188-9
22.
LevittHM, BambergM, CreswellJW, et al.Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report. Am Psychol, 2018; 73(1):26–46; doi: 10.1037/amp0000151
23.
BreeksemaJJ, NiemeijerAR, KredietE, et al.Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs, 2020; 34(9):925–946; doi: 10.1007/s40263-020-00748-y
24.
NielsonEM, MayDG, ForcehimesAA, et al.The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol, 2018; 9:132; doi: 10.3389/fphar.2018.00132
25.
NooraniT, Garcia-RomeuA, SwiftTC, et al.Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J Psychopharmacol, 2018; 32(7):756–769; doi: 10.1177/0269881118780612
26.
BelserAB, Agin-LiebesG, SwiftTC, et al.Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. J Humanist Psychol, 2017; 57(4):354–388; doi: 10.1177/0022167817706884
27.
SwiftTC, BelserAB, Agin-LiebesG, et al.Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol, 2017; 57(5):488–519; doi: 10.1177/0022167817715966
28.
WattsR, DayC, KrzanowskiJ, et al.Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Humanist Psychol, 2017; 57(5):520–564; doi: 10.1177/0022167817709585
29.
Agin-LiebesG, DavisAK. Psilocybin for the treatment of depression: A promising new pharmacotherapy approach. Curr Top Behav Neurosci, 2022; 56(101535383):125–140; doi: 10.1007/7854_2021_282
30.
KaelenM, GiribaldiB, RaineJ, et al.The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl), 2018; 235(2):505–519; doi: 10.1007/s00213-017-4820-5
31.
Agin-LiebesG, EkmanE, AndersonB, et al.Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis. J Humanist Psychol, 2024; 64(4):564–591; doi: 10.1177/00221678211022949
32.
MaloneTC, MennengaSE, GussJ, et al.Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol, 2018; 9(101548923):256; doi: 10.3389/fphar.2018.00256
33.
Garcia-RomeuA, GriffithsRR, JohnsonMW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev, 2014; 7(3):157–164.
34.
Agin-LiebesG, NielsonEM, ZingmanM, et al.Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. Psychol Addict Behav, 2024; 38(1):101–113; doi: 10.1037/adb0000935
35.
BogenschutzM, PodrebaracS, DuaneJ, et al.Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol, 2018; 9:100; doi: 10.3389/fphar.2018.00100
36.
AromatarisE, LockwoodC, PorrittK, et al.JBI Manual for Evidence Synthesis. JBI; 2024; doi: 10.46658/JBIMES-24-01
37.
TriccoAC, LillieE, ZarinW, et al.PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med, 2018; 169(7):467–473; doi: 10.7326/M18-0850
38.
PincombeJ, WilliamsM, CarruthersS, et al.Qualitative research on psilocybin-assisted psychotherapy for the treatment of mental health disorders. A Scoping Review Protocol, 2024; doi: 10.31234/osf.io/ga9p2
39.
PolitoV, LiknaitzkyP. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neurosci Biobehav Rev, 2022; 139:104706; doi: 10.1016/j.neubiorev.2022.104706
40.
OuzzaniM, HammadyH, FedorowiczZ, et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev, 2016; 5(1):210; doi: 10.1186/s13643-016-0384-4
KelmendiB, KichukSA, DePalmerG, et al.Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon, 2022; 8(12):e12135; doi: 10.1016/j.heliyon.2022.e12135
43.
BeaussantY, TarbiE, NigamK, et al.Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer, 2024; 130(7):1147–1157; doi: 10.1002/cncr.35024
44.
LewisBR, ByrneK, HendrickJ, et al.Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. Jps, 2023; 7(1):1–11; doi: 10.1556/2054.2022.00222
45.
PeckSK, FisherH, KimJ, et al.Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help. Psychedelics, 2024; 1(1):15–18.
46.
WattsR, LuomaJB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Context Behav Sci, 2020; 15:92–102; doi: 10.1016/j.jcbs.2019.12.004
47.
EvansJ, RobinsonOC, ArgyriEK, et al.Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One, 2023; 18(10):e0293349; doi: 10.1371/journal.pone.0293349
48.
McNameeS, DevenotN, BuissonM. Studying harms is key to improving psychedelic-assisted therapy—participants call for changes to research landscape. JAMA Psychiatry, 2023; 80(5):411–412; doi: 10.1001/jamapsychiatry.2023.0099
49.
BraunV, ClarkeV. To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales. Qual Res Sport Exerc Health, 2021; 13(2):201–216; doi: 10.1080/2159676X.2019.1704846
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
